State AR
Clinical Trials in Arkansas
Recruiting clinical trials with at least one study location in Arkansas. Data updated daily from ClinicalTrials.gov.
Top Conditions in Arkansas
Schizophrenia (4)Bipolar I Disorder (3)Breast Cancer (3)Duchenne Muscular Dystrophy (3)Oral Cavity Squamous Cell Carcinoma (2)Stage I Lip and Oral Cavity Cancer AJCC v8 (2)Stage II Lip and Oral Cavity Cancer AJCC v8 (2)Stage IV Lung Cancer AJCC v8 (2)Non-Muscle Invasive Bladder Urothelial Carcinoma (2)Major Depressive Disorder (2)Chronic Lymphocytic Leukemia (2)Depression (2)
Frequently Asked Questions — Clinical Trials in Arkansas
How many clinical trials are currently recruiting in Arkansas?
ClinicalMetric currently tracks 121 actively recruiting clinical trials with at least one location in Arkansas. The total number of registered studies—including active but not currently enrolling trials—is 121. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Arkansas?
Arkansas hosts clinical trials across a broad range of medical conditions, including Schizophrenia, Bipolar I Disorder, Breast Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Arkansas serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Arkansas?
To join a clinical trial in Arkansas, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Arkansas maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Arkansas
NCT05135091 Phase 3
Recruiting
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Tempo...
Condition
Mesial Temporal Lobe Epilepsy
Enrollment
88 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT04707872 N/A
Recruiting
Trifecta-Heart cfDNA-MMDx Study
Condition
Heart Transplant Rejection
Enrollment
300 pts
Location
United States, Australia, Canada
Sponsor
University of Alberta
NCT04566328 Phase 3
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Mu...
Condition
Plasma Cell Myeloma
Enrollment
1,450 pts
Location
United States, Puerto Rico
Sponsor
ECOG-ACRIN Cancer Research Gro
NCT06760637 Phase 3
Recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Bre...
Condition
Breast Cancer
Enrollment
1,020 pts
Location
United States, Argentina, Australia
Sponsor
Pfizer
NCT06442930 N/A
Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
Condition
Extubation
Enrollment
3,000 pts
Location
United States, Australia, Canada
Sponsor
University Health Network, Tor
NCT05066503 N/A
Recruiting
Nutritional Therapy for Delirium in Elderly Hospitalized Subjects
Condition
Subacute Delirium
Enrollment
60 pts
Location
United States
Sponsor
University of Arkansas
NCT06422923 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral...
Condition
Epilepsy, Temporal Lobe
Enrollment
10 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT06817382 Phase 1
Recruiting
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (I...
Condition
Duchenne Muscular Dystrophy
Enrollment
12 pts
Location
United States
Sponsor
Insmed Gene Therapy LLC
NCT06540963 Phase 2
Recruiting
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Condition
Neuroblastoma
Enrollment
98 pts
Location
United States
Sponsor
Giselle Sholler
NCT06739122 Phase 3
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants W...
Condition
Type 2 Diabetes
Enrollment
55 pts
Location
United States, Argentina, Mexico
Sponsor
Eli Lilly and Company
NCT05489705 N/A
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treat...
Condition
Obstructive Hypertrophic Cardiomyopathy
Enrollment
1,600 pts
Location
United States, Austria, France
Sponsor
Bristol-Myers Squibb
NCT05334069 N/A
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests...
Condition
Acute Lymphoblastic Leukemia
Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i
NCT06534983 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab...
Condition
Muscle-invasive Urothelial Carcinoma
Enrollment
362 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT06767683 Phase 2, Phase 3
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypers...
Condition
Narcolepsy Type 1
Enrollment
256 pts
Location
United States, Australia, Belgium
Sponsor
Alkermes, Inc.
NCT06806657 Phase 4
Recruiting
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching ...
Condition
Hereditary Angioedema
Enrollment
30 pts
Location
United States, Canada, Germany
Sponsor
CSL Behring
NCT06680830 Phase 2
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Posi...
Condition
Parkinson Disease
Enrollment
150 pts
Location
United States, Israel, Italy
Sponsor
Neuron23 Inc.
NCT07300969 Phase 2
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Condition
Major Depressive Disorder (MDD)
Enrollment
300 pts
Location
United States, Bulgaria, Czechia
Sponsor
Draig Therapeutics Ltd
NCT07398417 Phase 3
Recruiting
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal ...
Condition
Fibromyalgia
Enrollment
620 pts
Location
United States
Sponsor
Axsome Therapeutics, Inc.
NCT05287126 Phase 2
Recruiting
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Condition
Ulcerative Colitis
Enrollment
36 pts
Location
United States, Austria, Japan
Sponsor
Pfizer
NCT07558668 Phase 1
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic De...
Condition
Moderate to Severe Atopic Dermatitis
Enrollment
149 pts
Location
United States, Bulgaria, Denmark
Sponsor
Sitryx Therapeutics Ltd
NCT06172296 Phase 3
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Tre...
Condition
Ganglioneuroblastoma, Nodular
Enrollment
478 pts
Location
United States, Australia, Canada
Sponsor
National Cancer Institute (NCI
NCT06923423 N/A
Recruiting
Effectiveness, Implementation, and Cost of Cognitive Processing Therapy in Priso...
Condition
PTSD - Post Traumatic Stress Disorder
Enrollment
640 pts
Location
United States
Sponsor
University of Arkansas
NCT05946213 Phase 3
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in...
Condition
Prostate Adenocarcinoma
Enrollment
1,209 pts
Location
United States, Canada, Hong Kong
Sponsor
NRG Oncology
NCT06504446 Phase 2
Recruiting
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With...
Condition
Refractory or Unexplained Chronic Cough
Enrollment
455 pts
Location
United States, Belgium, Canada
Sponsor
Nocion Therapeutics
NCT06989437 Phase 2, Phase 3
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pan...
Condition
Cachexia
Enrollment
982 pts
Location
United States, Australia, Brazil
Sponsor
Pfizer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology